Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused...
Mental Health
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Canadian Men’s Health Foundation expands MindFit Toolkit to support more men with anxiety and depression
Providing greater access to online screening tools, resources and counselling with healthcare professionals MindFit Toolkit Canadian Men's Health Foundation launches...
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to...
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader...
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of...
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxietyMALVERN, Pa., Jan. 17, 2023 (GLOBE...
Canadian Centre for Agricultural Wellbeing welcomes TELUS Health as exclusive provider for mental health services
Services will help break down barriers to mental health support for farmers who may not have considered reaching out for...
VitalHub Announces Licensing Agreement With East Sussex Healthcare NHS Trust
TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce a licensing agreement...
Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors
AUSTIN, Texas, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Mindbloom, the world’s largest provider of ketamine therapy, announced Monday the launch...
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Heart to Heart CPR Raises Awareness of Ontario’s NEW Workplace Naloxone Requirements Effective June 1, 2023
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will...
BrainsWay Resolves Neuronetics Litigation
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Neuronetics Settles Litigation Against BrainsWay
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a...
Nexalin Technology CEO Provides Letter to Shareholders
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the...
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on...
Accolade Announces Participation in 25th Annual Needham Growth Conference
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th...
VitalHub Announces Five Year Licensing Contract With Wirral University Teaching Hospital
TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) is pleased to announce a five-year licensing...